BICO Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de BICO Group han disminuido a una tasa media anual de -81.8%, mientras que en la industria Life Sciences los beneficios crecieron en un 18.5% anualmente. Los ingresos han ido creciendo a una tasa media de 53.7% al año.

Información clave

-81.8%

Tasa de crecimiento de los beneficios

-77.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences	26.8%
Tasa de crecimiento de los ingresos	53.7%
Rentabilidad financiera	-34.6%
Margen neto	-70.6%
Próxima actualización de resultados	07 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero BICO Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BST:49Z Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	2,405	-1,697	1,537
30 Sep 23	2,459	-1,986	1,773
30 Jun 23	2,464	-1,849	1,884
31 Mar 23	2,483	-907	1,961
31 Dec 22	2,327	-85	1,818
30 Sep 22	2,278	41	1,857
30 Jun 22	1,995	-130	1,666
31 Mar 22	1,743	-224	1,354
31 Dec 21	1,378	-228	1,061
30 Sep 21	993	-188	749
30 Jun 21	744	-96	519
31 Mar 21	460	-50	342
31 Dec 20	369	-36	273
31 Aug 20	236	-62	218
31 May 20	213	-49	197
29 Feb 20	197	-24	176
30 Nov 19	173	-5	138
31 Aug 19	135	1	106
31 May 19	118	3	87
28 Feb 19	97	4	69
30 Nov 18	76	2	55
31 Aug 18	61	1	43
31 May 18	45	1	30
28 Feb 18	34	-2	24
30 Nov 17	27	-2	21
31 Aug 17	20	-1	16
31 Aug 16	6	-1	4

Ingresos de calidad: 49Z actualmente no es rentable.

Margen de beneficios creciente: 49Z actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 49Z no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 81.8% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 49Z en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 49Z no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Life Sciences (6.5%).

Rentabilidad financiera

Alta ROE: 49Z tiene una rentabilidad financiera negativa (-34.6%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

BICO Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)

First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)

Recent updates

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)

New major risk - Revenue and earnings growth

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

Group Chief Financial Officer recently bought €75k worth of stock

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Full year 2022 earnings released: kr13.00 loss per share (vs kr3.97 loss in FY 2021)

Independent Chairman of the Board recently sold €747k worth of stock

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

Now 28% undervalued

Third quarter 2022 earnings released

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

Forecast breakeven date moved forward to 2022

Second quarter 2022 earnings released

Forecast breakeven date moved forward to 2022

Now 22% undervalued after recent price drop

First quarter 2022 earnings released: kr0.68 loss per share (vs kr0.90 loss in 1Q 2021)

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

Now 23% undervalued after recent price drop

High number of new and inexperienced directors

BICO Group AB (Publ) Announces Board Appointments

Co-Founder recently bought €94k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

Co-Founder recently bought €1.9m worth of stock

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

Third quarter 2021 earnings released

Insider recently sold €1.1m worth of stock

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CEO & Director recently sold €17m worth of stock

Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020)

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

First quarter 2021 earnings released

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

New 90-day high: €30.00

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

New 90-day high: €25.25

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

New 90-day high: €21.65

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Full year earnings released - €1.47 loss per share

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

Desglose de ingresos y gastos
Beta